We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Roche and Sysmex Expand 25-Year Partnership to Foster More Sustainable Diagnostic Solutions

By LabMedica International staff writers
Posted on 04 Aug 2023

Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan) have expanded their Global Business Partnership Agreement. More...

The renewed agreement reinforces the commitment of both companies to their long-established collaboration. Under the revised terms, Roche, which has been collaborating with Sysmex for 25 years, will continue to offer Sysmex's hematology products, complementing its comprehensive laboratory solutions portfolio. The Global Business Partnership Agreement between Roche and Sysmex promises to assist patients requiring diagnostic solutions and aims to enhance the efficiency and effectiveness of lab testing by offering integrated in-vitro diagnostics (IVD) technologies through a single provider.

The commercial and R&D collaboration between Roche and Sysmex was initiated in 1998, and the companies have since consistently strengthened their partnership. In 2020, both companies signed the Global Business Partnership Agreement to broaden their partnership further and enhance the customer experience. As of 2023, with updated terms and an expanded scope, both companies have reaffirmed their long-standing partnership and commitment to fostering a more sustainable future for society. The revised non-exclusive agreement ushers in a new dimension of cooperation, incorporating an additional eco-social agreement to jointly investigate more sustainable diagnostic solutions. By extending their long-standing collaboration beyond the current portfolio, both companies have demonstrated their commitment to seeking more sustainable solutions.

“We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable diagnostics solutions,” said Matt Sause, CEO of Roche Diagnostics. “Roche and Sysmex both have a long-standing history of delivering reliable and innovative solutions for patients and I am very happy to see this collaboration grow.”

“We are pleased to announce the renewal of our partnership with Roche, reaffirming our commitment to long-term collaboration,” added Kaoru Asano, President of Sysmex Corporation. “Developing our partnerships in the field of diagnostics even further and addressing enduring eco-social challenges represents a significant milestone in advancing our alliance to the next level. Together, we firmly believe in making even greater contributions to our customers in laboratories and creating a sustainable society."

Related Links:
Roche
Sysmex Corporation


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Immunofluorescence Analyzer
IFA System
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.